Please provide your email address to receive an email when new articles are posted on . The FDA approved the GLP-1 receptor agonist dulaglutide for the reduction of major adverse cardiovascular events ...
Bloodstream infections present many challenges to clinicians. The number of hospitalized patients with blood-stream infection continues to increase, and the number of newly available antimicrobial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback